Indian Journal of Medicine and Healthcare

Open Access Open Access  Restricted Access Subscription Access

Effects of Oral Contraceptives - Microgynon and Primolut-n on Plasma Creatinine of Wistar Albino Rat


Affiliations
1 Department of Biochemistry, Faculty of Science, PMB 5323, University of Port Harcourt, Rivers State, Nigeria
 

Oral contraceptives such as Microgynon a combined pill (0.15mg levonorgestrel and 0.03mg ethinylestradiol) and Primolut -N a mini pill (5mg norethisterone) were investigated for their Invivo effects on wistar albino rat plasma creatinine levels. Test results showed that the drugs raised plasma creatinine levels in a concentration dependent manner but the increase in creatinine levels were not time dependent. The highest increase of 300% was observed for Microgynon at the highest concentration of 3.60μg/100g body wt (354 ± 0.00 μmol/l). The highest increase obtained for Primolut-N was 182.75% (236 ± 29.50μmol/l). The differences in dosage were statistically significant on the effect of the drugs on the plasma creatinine levels at 95.0% confidence level (P<0.05). Creatinine is a protein breakdown product and its level is a reflection of the bodies muscle mass, but unlike urea, creatinine is almost independent of diet. Since the blood level reflects the balance between production and excretion, it varies little from day to day if renal function remains constant. This result makes it imperative that kidney function tests are needed for women before using these drugs.

Keywords

Oral Contraceptives, Microgynon, Primolut-n, Plasma Creatinine
User
Notifications

  • Avonts D, Sercu M, Heyrich P, Vandermeeren I, Meheus A and Pilot P (1990) Incidence of uncomplicated genital infections in women using oral contraceptives or an uterine device: A prospective study. Sexually transmited dis. 17 (1), 23-29

  • Briggs M (1976) Biochemical effects of oral contraceptives. Adv. Steroid Biochem. Pharmacol. 5, 65 -160

  • Briggs M (1978) Biochemical basis for the selection of oral contraceptives. Int. J. Gynecol. Obstet. 39 (8), 19

  • CHPE, Division of Reproductive Health, (1984) Family planning methods and practice : Africa. US. Public Health service. Department of Health and Human Services, Atlanta Georgia 30333. USA.

  • Grimes DA, Mishell DR Jr and Speroff L (1993) Contraceptive choices for women with medical problems. Am. J. Obstet. Gynecol. 198, 625-630.

  • Grinspoon SK, Friedman AJ, Miller KK, Lippman J, Olson WH and Warren MP (2003) Effects of a triphasic combination oral contraceptive containing Norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. J. Clin. Endocrinol. Metabolism. 88 (8), 3651-3656.

  • Henderson M, Dorflinger J, Fishman J, Foster HW and Gump FE, Hellman S, Hulka BS, Mattison DR, McKay SAR, Moses LE, Norsigian J, Potts M, Schwartz NB, Smith H, Stolley PD and Wiggins PV (1991) Oral contraceptives and breast cancer. National Academy Press. 1-77

  • Henry RJ (1974) Clinical chemistry, principles and technics, 2nd Edn, Harper and Row. pp: 525.

  • Liu SL and Lebrun CM (2006) Effects of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br. J. Sports Med. 40 (1), 11-24.

  • Kay CR, Crombie DL, Kuenssberg EV, Pinsent, RJFH, Richards B, Smith A and Crowther CH (1974) Oral contraceptives and health. The Royal college of general practitioners study. Am. J. Obstet. Gynecol. 10,150.

  • Shelepova T, Nafziger AN and Victory J (2005) Effect of a triphasic oral contraceptive on drug metabolizing enzyme activity as measured by the validated cooperstown 5+1 cocktail. J. clin. Pharmacol. 45, 1413 -1421.

  • Skouby SO and Jesperson J (1990) Oral contraceptives in the nineties, metabolic aspects, facts and fiction. Am. J. Obstet. Gynecol. 163, 276.

  • Smith RP and Sizto R (1983) Metabolic effects of two triphasic formulations containing ethinyl estradiol and dl-norgestrel. J. Contraception. 28 (2), 189-199.

  • Vessey M, Lawless M and Yeates D (1982) Efficacy of different contraceptive methods. Lancet. 1, 841.

  • Wootton IDP and Freeman H (1982) Microanalysis in medical biochemistry, 6th edition, Churchill Livingstone Inc. NY, U S A. 1-190.


Abstract Views: 821

PDF Views: 344




  • Effects of Oral Contraceptives - Microgynon and Primolut-n on Plasma Creatinine of Wistar Albino Rat

Abstract Views: 821  |  PDF Views: 344

Authors

N. F. Okoye
Department of Biochemistry, Faculty of Science, PMB 5323, University of Port Harcourt, Rivers State, Nigeria
A. A. Uwakwe
Department of Biochemistry, Faculty of Science, PMB 5323, University of Port Harcourt, Rivers State, Nigeria
E. O. Ayalogu
Department of Biochemistry, Faculty of Science, PMB 5323, University of Port Harcourt, Rivers State, Nigeria

Abstract


Oral contraceptives such as Microgynon a combined pill (0.15mg levonorgestrel and 0.03mg ethinylestradiol) and Primolut -N a mini pill (5mg norethisterone) were investigated for their Invivo effects on wistar albino rat plasma creatinine levels. Test results showed that the drugs raised plasma creatinine levels in a concentration dependent manner but the increase in creatinine levels were not time dependent. The highest increase of 300% was observed for Microgynon at the highest concentration of 3.60μg/100g body wt (354 ± 0.00 μmol/l). The highest increase obtained for Primolut-N was 182.75% (236 ± 29.50μmol/l). The differences in dosage were statistically significant on the effect of the drugs on the plasma creatinine levels at 95.0% confidence level (P<0.05). Creatinine is a protein breakdown product and its level is a reflection of the bodies muscle mass, but unlike urea, creatinine is almost independent of diet. Since the blood level reflects the balance between production and excretion, it varies little from day to day if renal function remains constant. This result makes it imperative that kidney function tests are needed for women before using these drugs.

Keywords


Oral Contraceptives, Microgynon, Primolut-n, Plasma Creatinine

References